國檢集團(603060.SH):控股股東擬以5000萬-8000萬元增持公司股份 已增持193.0398萬股
格隆匯3月17日丨國檢集團(603060.SH)公佈,公司控股股東中國建築材料科學研究總院有限公司(“中國建材總院”)於2022年3月17日通過上海證券交易所競價交易系統增持公司股票193.0398萬股,佔公司總股本的比例為0.32%。
自首次增持日2022年3月17日起至2022年9月16日止,中國建材總院擬繼續增持公司股份,累計增持金額(含本次增持金額)不低於5000萬元,不高於8000萬元。
此次增持計劃增持價格不高於25元/股。若增持計劃實施期間公司有派息、送股、資本公積金轉增股本、配股等除權除息事項,中國建材總院將對增持計劃進行相應調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.